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INTRODUCTION
Thrombotic thrombocytopenic purpura 
(TTP) typically occurs with a pentad of si-
gns: thrombocytopenia, anemia, neurologi-
cal symptoms, fever and renal involvement. 
TTP is a rare disease, with an incidence of 
5-10 cases per year per million. The inciden-
ce is 2-3 times higher in females, though it 
affects both males and females [1-3].
TTP occurs in two forms: a congenital 
form and an acquired form. The congenital 
form is due to mutations in the ADAMTS13 
gene (which is located on chromosome 9q34 
and codes for the metalloprotease) and it 
is inherited as an autosomal recessive con-
Why we describe this case
To highlight the importance of treating 
suspected cases of TTP even before la-
boratory confirmation. In fact, various 
studies in literature3 have confirmed a 
reduction in 30-day mortality and a si-
gnificant increase in platelet count after 
apheretic therapy in combination with 
corticosteroids and/or immunosuppres-
sive drugs. Moreover, mortality asso-
ciated with thrombotic thrombocytope-
nic purpura is generally high, if it is not 
carried out with plasmapheresis. Plasma 
exchange has decreased the overall mor-
tality rate to 10%
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Abstract
An 84 year-old female was admitted to our Department of Vascular Internal Medicine after a 
sudden onset of weakness on her right side and aphasia along with signs of myocardial ischemia 
from Electrocardiogram (EKG). Clinical and blood exams led to a suspicion of Moschcowitz 
syndrome, which was reinforced by the presence of numerous schistocytes on a peripheral blood 
smear. 
Due to a rapid deterioration of vital signs as well as alertness, the patient underwent an 
emergency transfusion and plasmapheresis treatment as recommended by American Society of 
Apheresis (ASFA) guidelines: one plasma volume was replaced with fresh frozen plasma (FFP) 
every 24 hours, for the first eight days, in order to reach at least a level of 150,000 platelets/mm3 
over three consecutive days accompanied by a decrease in LDH until to 670 UI/l. 
After this therapy, the clinical picture significantly improved with a complete recovery of 
consciousness and the disappearance of neurological defects. 
Examinations to determine the etiology made us hypothesize a secondary status of thrombotic 
thrombocytopenic purpura due to an autoimmune disorder compatible with Sjogren’s syndrome. 
The patient was discharged and prescribed prednisone. 
Currently the patient is in good clinical condition and continues the therapy with prednisone 
(5 mg/die). 
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dition. Usually, but not always, it occurs at 
birth or in childhood [4-6].
Furthermore, there are two main types of 
acquired TTP: immune-mediated forms, 
due to autoantibodies against ADAMTS13 
[7-11], and those probably secondary to 
massive endothelial stimulation, with con-
sequent release of ULVWF multimers in 
amounts exceeding the system’s ability 
to degrade them, despite the presence of 
normal or only slightly reduced levels of 
ADAMTS13 [12]. Both these pathogenic 
situations are usually triggered by concomi-
tant factors which cause widespread endo-
thelial activation.
The most common physiological or patho-
logical conditions present in the immune-
mediated forms, which are often associa-
ted with very low or undetectable levels of 
ADAMTS13 (less than 10% of the normal), 
are pregnancy, infections, autoimmune dise-
ases, and the use of drugs such as ticlopidine 
and clopidogrel. In most cases TTP occurs 
as a single, sporadic acute episode, but the-
re are chronic recurrent forms (20- 30% of 
the cases). The chronic recurrent forms may 
have a genetic basis or be associated with 
the formation of autoantibodies, whereas the 
forms associated with malignancy or tran-
splantation present as acute episodes with a 
low propensity to recur (in part because of 
the high mortality rate) [13].
Plasma exchange with plasma replace-
ment has significantly improved clinical 
outcome. No other intervention has had 
such a significant impact on the efficacy of 
treatment [14].
CASE REPORT
An 84 year-old female was admitted to our 
Department of Vascular Internal Medicine 
after a sudden onset of weakness on right 
side of her body and aphasia.
The patient reported a medical history 
including: an abdominal infrarenal aortic 
aneurysm that required the positioning of 
an endoprothesis many years before, a slight 
iron anemia and a chronic erythematous ga-
stritis. Over the past few months, the patient 
had presented an erythematous, edematous, 
crusted dermatitis at the level of her fore-
arms and trunk, in the absence of pruritus, 
associated with worsening asthenia. One 
month prior to admission, she had a bout 
of diarrhea and fever that lasted for about 
a week and then regressed spontaneously.
At ER, a brain CT scan was performed to 
rule out for the presence of acute ischemic 
lesions and / or hemorrhagic lesions. An 
EKG evidenced a sinus tachycardia with 
signs of myocardial ischemia in the lateral 
leads. On admission to our department, the 
patient appeared agitated and disoriented. 
Neurologic examination showed right sided 
hemineglect and hemiplegia. No relevant si-
gns were detected on physical examination 
of the chest, abdomen and heart. Erythe-
matous papular patches, slightly hypopig-
mented in the middle, and pink at the edge, 
were detected on the skin, on both forearms.
Blood tests resulted: anemia with 9.2 g/dl 
Hb, RBC 3340 x 103/mm3, erythrocyte indi-
ces within standard values, thrombocytope-
nia with 10,000/mm3 confirmed during the 
control blood sample, LDH 1619 UI/l (n.v.: 
up to 450 UI/l), total bilirubin 1.60 mg/dl 
with a value on indirect bilirubin 1.13 mg/
dl, reticulocytes 33 ‰, haptoglobin 7 mg/
dl (n.v.: 30-200 mg/dl), INR 1.11, a PTT-
Ratio 1.03, fibrinogen 351 mg/dl, BUN 60 
mg/dl, creatinine 0.80 mg/dl. During the 
first hours after admission, the patient de-
veloped fever along with an increase in the 
miocardiolysis index (troponin: 6.33 ng/
ml), deterioration of vital signs (PA 90/60 
mmHg, RR 30/min, oxygen saturation 88% 
in air) and alertness (Glasgow Coma Scale 
4). A further Hb reduction reaching 7.8 g/
dl, was also documented, as well as a reduc-
tion in platelet levels: 6000/mm3.
Clinical and laboratory findings suggested 
TTP (Moschcowitz syndrome). Furthermo-
re, a Coombs’test was performed (resulted 
negative) and a peripheral blood smear sho-
wed the presence of numerous schistocytes 
per field. For this reason, the patient un-
derwent an emergency transfusion with pa-
cked red blood cells and plasmapheresis 
treatment with COBE- SPECTRA. Spe-
cifically, one plasma volume was replaced 
with fresh frozen plasma (FFP) having a 
balance of 100%, delivered by an Arrow type 
central venous catheter. According to ASFA 
guidelines [14 ], treatment was administered 
every 24 hours, for the first eight days, in 
order to reach at least a level of 150,000 pla-
telets/ mm3 over three consecutive days, ac-
companied by a decrease in LDH until to 
670 UI/l (Table I). Following this, the cli-
nical picture improved with a recovery of 
consciousness and a complete disappearan-
ce of neurological defects.
After the therapy, the patient showed 
the presence of multiple positive predictive 
Session Hb (g/dl) Plateletes (x103/ul) LDH (UI/l)
1 10.6 7 1984
2 10.2 16 1052
3 10.31 39 /
4 10.7 80 711
5 11.6 136 711
6 11.5 166 /
7 11.6 181 671
8 10.9 190 /
Table I. Laboratory 
trend after plasma 
exchange (PEX)
87
©SEEd Tutti i diritti riservati
Clinical  Management  Issues   2013; 7(3)
M. S. Pioli Di Marco, F. Guercini, C. Busti, O. Minelli
factors such as increase of platelet count, 
decrease in levels of LDH and a survival of 
nine days after the onset of the disease. This 
regimen was then performed every day for 
three weeks, achieving a constant platelet le-
vel of around 150,000/mm3, until discharge. 
During the sessions, adverse effects related 
to plasmapheresis such as allergic reactions 
to plasma, systemic infections, catheter ob-
struction or venous thrombosis were never 
reported [15].
Furthermore, examinations were carried 
out to determine the etiology:
 y Activity assay of ADAMTS13, carried 
out before plasmapheresis: <6% (range 
50-150%);
 y Screening for infectious diseases, resulted 
negative: blood cultures, urine cultures, 
coprocultures, parassitolological examina-
tion of stools, search for antigen entero-
haemorrhagic E. coli pathogenic VTEC 
O.157, serology for hepatotropic viruses, 
Toxoplasmosis, rubella, CMV, HSV, Co-
xiella Burnetii, Adenovirus, Mycoplasma;
 y Screenings for autoimmunities, resulted 
positive: ANA 194.2 UI/ml (n.v. < 5UI/
ml), Anti-DNA Ab negative, confirmed 
in a further control, anti-ENA positive 
with positivity Anti-SSA/Ro 52 Ab 66.43 
UI/L and Anti SSA/Ro 60 Ab 12.28 
UI/L (n.v. <7 UI/ml negative; 7-10 UI/
ml borderline; >10 UI/ml positive).
The patient refused to undergo a sore 
biopsy.
Given the above, we hypothesized a se-
condary status of TTP due to an autoim-
mune disorder compatible with Sjogren’s 
syndrome. The patient was discharged and 
was prescribed prednisone at a dosage of 
75 mg for the first two weeks, followed by 
50 mg for another two weeks. After ten 
months of progressively decrease in therapy, 
currently the patient takes prednisone 5 mg/
die. Currently, the general clinical condition 
remains good, and she is able to walk alone 
with minimal support. The platelet level re-
mains steady at around 144,000/mm3 with 
Hb 11.4 g/dl.
DISCUSSION
The acquired form of TTP, secondary to 
autoimmune disease, accounts for appro-
ximately 50% of all cases of TTPs, but in 
many cases their pathophysiology is still 
uncertain. As well, the recurrence rate of 
all TTPs is above 35% with an excessively 
high mortality rate. Today the only tre-
atment that has proven to be effective in 
changing the prognosis of these patients 
is apheresis with plasma exchange. Before 
the plasma exchange (PEX) era, only 10% 
of patients survived [16]: initials report of 
PEX from 1981 to 1991 already described 
an increase in the survival rates of up to 70-
79% [17-19].
According to the proponents of the infu-
sion of plasma, the benefit would be related 
to the administration of a deficient sub-
stance in patients with TPP. On the other 
side, the proponents of PEX argue that the 
advantage of this therapeutic option consists 
not only in the administration of a deficient 
factor, but also in the elimination of toxic 
substances, which occurs during the proce-
dure PEX [19].
This treatment should be promptly taken 
into consideration also in the only suspect 
of TTP, even before laboratory confirma-
tions. Various studies in literature [20] have 
confirmed a reduction in 30-day mortality 
and a significant increase in platelet count 
after apheretic therapy in combination with 
corticosteroids and/or immunosuppressive 
drugs. Corticosteroids in combination with 
plasmapheresis increase the complete re-
At ER, a brain CT scan was performed to 
rule out for the presence of acute ischemic 
lesions and / or hemorrhagic lesions. An 
EKG evidenced a sinus tachycardia with 
signs of myocardial ischemia in the lateral 
leads. On admission to our department, the 
patient appeared agitated and disoriented. 
Neurologic examination showed right sided 
hemineglect and hemiplegia. No relevant si-
gns were detected on physical examination 
of the chest, abdomen and heart. Erythe-
matous papular patches, slightly hypopig-
mented in the middle, and pink at the edge, 
were detected on the skin, on both forearms.
Blood tests resulted: anemia with 9.2 g/dl 
Hb, RBC 3340 x 103/mm3, erythrocyte indi-
ces within standard values, thrombocytope-
nia with 10,000/mm3 confirmed during the 
control blood sample, LDH 1619 UI/l (n.v.: 
up to 450 UI/l), total bilirubin 1.60 mg/dl 
with a value on indirect bilirubin 1.13 mg/
dl, reticulocytes 33 ‰, haptoglobin 7 mg/
dl (n.v.: 30-200 mg/dl), INR 1.11, a PTT-
Ratio 1.03, fibrinogen 351 mg/dl, BUN 60 
mg/dl, creatinine 0.80 mg/dl. During the 
first hours after admission, the patient de-
veloped fever along with an increase in the 
miocardiolysis index (troponin: 6.33 ng/
ml), deterioration of vital signs (PA 90/60 
mmHg, RR 30/min, oxygen saturation 88% 
in air) and alertness (Glasgow Coma Scale 
4). A further Hb reduction reaching 7.8 g/
dl, was also documented, as well as a reduc-
tion in platelet levels: 6000/mm3.
Clinical and laboratory findings suggested 
TTP (Moschcowitz syndrome). Furthermo-
re, a Coombs’test was performed (resulted 
negative) and a peripheral blood smear sho-
wed the presence of numerous schistocytes 
per field. For this reason, the patient un-
derwent an emergency transfusion with pa-
cked red blood cells and plasmapheresis 
treatment with COBE- SPECTRA. Spe-
cifically, one plasma volume was replaced 
with fresh frozen plasma (FFP) having a 
balance of 100%, delivered by an Arrow type 
central venous catheter. According to ASFA 
guidelines [14 ], treatment was administered 
every 24 hours, for the first eight days, in 
order to reach at least a level of 150,000 pla-
telets/ mm3 over three consecutive days, ac-
companied by a decrease in LDH until to 
670 UI/l (Table I). Following this, the cli-
nical picture improved with a recovery of 
consciousness and a complete disappearan-
ce of neurological defects.
After the therapy, the patient showed 
the presence of multiple positive predictive 
Session Hb (g/dl) Plateletes (x103/ul) LDH (UI/l)
1 10.6 7 1984
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mission rate and decrease the relapse rates. 
This latter result is due to the removal of the 
Unusually Large Von Willebrand Factor 
(ULVWF) and anti ADAMTS 13 Antibo-
dies, while steroids reduce anti- ADAMTS 
13 Antibodies production [21].
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